Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:2.1.1.148 (Thy1)
 1,210 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

BALB/c mice were inoculated intraperitoneally (i.p.) with MOPC-104E syngeneic plasmacytoma cells and seven days later the mice were treated with i.p. cyclophosphamide (CY). All mice exhibited a complete regression of MOPC-104E, and in addition acquired the resistance to second challenge of MOPC-104E, but not to syngeneic Meth-A fibrosarcoma. Following CY treatment, a large number of viable MOPC-104E cells were seen in the peritoneal cavity of the mice on day 7, and then they decreased and disappeared on day 14. By contrast, athymic BALB/c nude mice with MOPC-104E did not respond to CY and died. Only a transient decrease in the number of tumor cells was observed in the peritoneal cavity of nude mice. Following CY treatment, whole peritoneal cells (tumor cells and peritoneal exudate cells) was not transplanted to conventional mice, while transplantation was possible following treatment of whole peritoneal cells with anti-Thy1, anti-Lyt 1 or anti-Lyt 2 plus complement (C). The in vivo anti-tumor activity of spleen cells of mice in regression was nullified by treatment with anti-Thy 1 and anti-Lyt 1 plus C, but not anti-Lyt 2 plus C. These results indicate that CY administration results in only a transient decrease of tumor cell number and that an induction of Lyt 1 +, Lyt 2 + T cells in the peritoneal cavity and Lyt 1 + T cells in spleen may be responsible for a complete disappearance of tumor cells.
 ...
PMID:Induction by cyclophosphamide administration of two distinct anti-tumor effector cells at tumor site and spleen of mice transplanted with MOPC-104E plasmacytoma. 253 33

Studies were undertaken to determine a possible structural relationship between the secretory component (SC) and the receptor for IgA (Fc alpha R). An IgA-mediated rosetting technique was used to assess the presence of Fc alpha R+ cells in various lymphoid tissues from normal BALB/c mice and mice bearing an IgA plasmacytoma (MOPC 315). Tissues from the MOPC 315-bearing BALB/c mice were found to have a significantly higher percentage of Fc alpha R+ cells; thus, nonadherent spleen cells from MOPC 315-bearing mice were used as a source of Fc alpha R+ cells in these studies. The cells were preincubated with anti-SC and then assayed for the ability of IgA to bind to the Fc alpha R. Antisera to SC from various species inhibited the formation of IgA-mediated rosettes, although preincubation of the Fc alpha R+ cells with antisera directed against other cell surface molecules (e.g., Thy1.2, Lyt1, Lyt2, Fc gamma R, MHC class I and II) or preimmune sera had no significant effect on IgA-mediated rosette formation. Preabsorption of the anti-SC with secretory IgA or with free SC removed the inhibitory effect; preabsorption with myeloma IgA had no effect. These data suggest that SC and Fc alpha R are related serologically and may be structurally related, possible in the IgA-binding region.
 ...
PMID:Antisera to the secretory component recognize the murine Fc receptor for IgA. 278 69

The possibility of active specific immunotherapy using interleukin-1 (IL-1) plus sonicated tumor supernatant (SS) was examined in a murine tumor model. The growth of intraperitoneally or subcutaneously inoculated plasmacytoma MOPC104E, which is syngeneic to BALB/c mice, was significantly suppressed by intraperitoneal pretreatment with IL-1 and SS from MOPC104E cells (MOPC-SS), on days 10, 7, and 4 before tumor inoculation. Pretreatment with IL-1 plus MOPC-SS or MethA-SS (SS from MethA cells) suppressed the growth of subcutaneous tumor of only the corresponding tumor cells, indicating the development of tumor-specific immunity in vivo. The splenic cells of immunized mice with IL-1 and MOPC-SS showed tumor neutralizing activity. However, their tumor neutralizing activity was abrogated when they were treated in vitro with anti-Thy1.2 or anti-L3T4 plus complement. Moreover, when combined with indomethacin per oral, IL-1 plus MOPC-SS significantly suppressed the growth of established subcutaneous tumor and prolonged survival of post-operative mice. These results suggest that this new type of active specific immunotherapy could be a useful method for cancer immunotherapy, especially when combined with oral indomethacin.
 ...
PMID:A new model of active specific immunotherapy using interleukin-1 and sonicated tumor supernatant in murine tumor system. 864 45